Table 3:
Association between transplant status and cancer-specific mortality among local-stage cancer patients receiving curative treatment *
| Cancer site, and transplant status | Cancer-specific deaths | Cancer-specific mortality rate† | aHR1‡ | 95%CI | aHR2§ | 95%CI |
|---|---|---|---|---|---|---|
| Colorectum | ||||||
| Recipient | 46 | 38.2 | 2.59 | (1.94, 3.47) | 2.77 | (2.07, 3.70) |
| Non-recipient | 32,305 | 19.3 | 1 | referent | 1 | referent |
| Lung | ||||||
| Recipient | 117 | 123.6 | 1.46 | (1.22, 1.75) | 1.66 | (1.38, 1.99) |
| Non-recipient | 47,405 | 85.7 | 1 | referent | 1 | referent |
| Melanoma | ||||||
| Recipient | 56 | 37.8 | 3.88 | (2.98, 5.04) | 3.82 | (2.94, 4.97) |
| Non-recipient | 16,595 | 10.5 | 1 | referent | 1 | referent |
| Breast | ||||||
| Recipient | 36 | 17.1 | 1.99 | (1.43, 2.76) | 2.08 | (1.50, 2.88) |
| Non-recipient | 50,563 | 9.9 | 1 | referent | 1 | referent |
| Prostate | ||||||
| Recipient | 30 | 7.3 | 1.64 | (1.14, 2.34) | 1.60 | (1.12, 2.29) |
| Non-recipient | 36,891 | 7.9 | 1 | referent | 1 | referent |
| Kidney | ||||||
| Recipient | 78 | 19.9 | 1.52 | (1.22, 1.90) | 1.56 | (1.25, 1.96) |
| Non-recipient | 10,396 | 17.2 | 1 | referent | 1 | referent |
| DLBCL | ||||||
| Recipient | 49 | 67.7 | 1.54 | (1.16, 2.04) | 1.44 | (1.09, 1.91) |
| Non-recipient | 6,120 | 53.0 | 1 | referent | 1 | referent |
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma
Analyses were restricted to local stage cancers. Curative treatment is defined as receipt of surgery for colorectal, breast, and kidney cancers and melanoma; surgery or radiation therapy for lung and prostate cancers; and chemotherapy for DLBCL.
Mortality rate per 1000 person-years.
Cox regression models were adjusted for age (<40,40–84 in 5 year increments,85+), sex, race (white,black,other), stage (local,regional,distant,unknown), and diagnosis year (1987–1991, 1992–1996, 1997–2001, 2002–2005, 2006–2009, 2010–2014).
Cox regression models were adjusted for factors in HR1 plus additional treatment received including: surgery received (yes,no,unknown), radiotherapy received (yes,no,unknown), chemotherapy received (yes,no,other). Breast and prostate cancer models were also adjusted for hormone therapy (yes,no,unknown). DLBCL was not adjusted for surgery, but was adjusted for immune therapy (yes,no,unknown).